{"filing":{"accession_number":"0001213900-26-068390","cik":"0001560293","ticker":"TNONW","company_name":"Tenon Medical, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294657-8k_tenon.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026068390/ea0294657-8k_tenon.htm"},"events":[{"id":10372,"run_id":9095,"accession_number":"0001213900-26-068390","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"The company approved the 2026 Executive Compensation Plan on February 26, 2026, increasing base salaries by 5% for CEO Steven M. Foster ($420,000), CFO Kevin Williamson ($330,750), and COO Richard Ginn ($304,500), and modified annual bonus opportunities. Additionally, the company amended Richard Ferrari's consulting agreement as Executive Chairman, extending his term through May 6, 2027 at $180,000 annually.","company_name":"Tenon Medical, Inc.","ticker":"TNONW","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":6671,"accession_number":"0001213900-26-068390","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.35,"reasoning":"Item 1.01 indicates entry into a material definitive agreement, but the actual substance is incorporated by reference from Item 5.02, which typically covers executive changes (departures or appointments). Without the full text of Item 5.02, the specific nature of the material agreement cannot be determined—it could relate to an executive severance arrangement, employment agreement, or other compensation-related contract. The cross-reference creates ambiguity about whether this is truly an M\u0026A or material contract event versus an executive compensation or departure matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:06.132978+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6672,"accession_number":"0001213900-26-068390","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two compensatory arrangements: (1) the 2026 Executive Compensation Plan approved February 26, 2026, which increased base salaries by 5% for CEO Steven M. Foster ($420,000), CFO Kevin Williamson ($330,750), and COO Richard Ginn ($304,500), and modified annual bonus opportunities to 50%, 35%, and 35% of base salary respectively, plus additional bonuses up to $100,000, $70,000, and $50,000; and (2) an amendment to Richard Ferrari's consulting agreement extending his term as Executive Chairman through May 6, 2027 at $180,000 annually. These are compensatory arrangements for named executives disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:06.132978+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6671,"accession_number":"0001213900-26-068390","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.35,"reasoning":"Item 1.01 indicates entry into a material definitive agreement, but the actual substance is incorporated by reference from Item 5.02, which typically covers executive changes (departures or appointments). Without the full text of Item 5.02, the specific nature of the material agreement cannot be determined—it could relate to an executive severance arrangement, employment agreement, or other compensation-related contract. The cross-reference creates ambiguity about whether this is truly an M\u0026A or material contract event versus an executive compensation or departure matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:06.132978+00:00","company_name":"Tenon Medical, Inc.","ticker":"TNONW","filing_date":"2026-06-12"},{"id":6672,"accession_number":"0001213900-26-068390","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two compensatory arrangements: (1) the 2026 Executive Compensation Plan approved February 26, 2026, which increased base salaries by 5% for CEO Steven M. Foster ($420,000), CFO Kevin Williamson ($330,750), and COO Richard Ginn ($304,500), and modified annual bonus opportunities to 50%, 35%, and 35% of base salary respectively, plus additional bonuses up to $100,000, $70,000, and $50,000; and (2) an amendment to Richard Ferrari's consulting agreement extending his term as Executive Chairman through May 6, 2027 at $180,000 annually. These are compensatory arrangements for named executives disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:06.132978+00:00","company_name":"Tenon Medical, Inc.","ticker":"TNONW","filing_date":"2026-06-12"}]}